1435-55-8 | Page 2 of 2 | Catalyst ligands

1435-55-8, Hydroquinidine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

From dihydroquinidine To a 0 C. solution of 1.22g dihydroquinidine (0.0037 mol) in 30mL of CH2 Cl2 was added 0.78mL of Et3 N (0.0056 mol; 1.5 eq), followed by 0.71mL of p-chlorobenzoyl chloride (0.005 mol; 2 eq) in 1mL CH2 Cl2 After stirring 30 minutes at 0 C. and 1 hour at room temperature, the reaction was quenched by the addition of 10% Na2 CO3 (20mL). After separation, the aqueous layer was extracted with three 10mL portions of CH2 Cl2. The combined organic layers were dried over Na2 S04 and the solvent removed under vacuum. The crude product was purified as described above. Dihydroquinidine p-chlorobenzoate (1) was obtained in 91% yield (1.5g) as a white foam.

1435-55-8, 1435-55-8 Hydroquinidine 16401293, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Massachusetts Institute of Technology; US4965364; (1990); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1435-55-8,Hydroquinidine,as a common compound, the synthetic route is as follows.

EXAMPLE 23 Synthesis of Methylphenylcarbamoyl dihydroquinidine (MPC-DHQD) Dihydroquinidine (1.4 g, 4.3 mmol, 1 eq) was dissolved in 15 ml of CH2 Cl2 under nitrogen atmosphere in a 3-necked 100 ml round bottom flask. At room temperature, 2 ml of triethylamine (14.4 mmol, 3.3 eq) was added to the solution and stirred for 30 minutes. N-methyl-N-phenylcarbamoyl chloride (1.6 g, 9.4 mmol, 2.2 eq) was dissolved in 6 ml CH2 Cl2 and added to the reaction mixture dropwise via an addition funnel. The reaction mixture was stirred under N2 for three days before reaching reaction completion. 50 ml of 2N NaOH were added, and the phases were separated. The CH2 Cl2 layer was saved, and the aqueous phase was extracted with 50 ml of CH2 Cl2. The CH2 Cl2 phases were combined and dried over MgSO4 before being concentrated down to afford a gummy pink material. Purification via flash chromatography (silica gel, 95.5 EtOAc/Et3 N, v/v) afforded a yellow material which was then crystallized from CH3 CN to obtain white starlike crystals (1.27 g, 65% yield). Characterization: mp. 119-120 C. High resolution mass spec; calculated molecular mass–459.25217 amu, found–459.2519 amu. 1 H NMR (300 MHz, CDCl3 with TMS); 8.7 delta (d, 1H), 8.0 delta (d,1H), 7.2-7.4 delta (m, 7H) 6.4 delta (d, 1H), 3.8 delta (s,3H), 3.3 delta (s,3H), 3.1 delta (1H), 2.8 delta (q, 1H), 2.6 delta (m, 3H), 1.7 delta (s,2H), 1.3-1.4 delta (m7H), 0.9 delta (t, 3H). 13 C NMR (75 MHz, CDCl3 with TMS): 12.1 delta, 23.9 delta, 25.3 delta, 26.2 delta, 27.3 delta, 37.5 delta, 38.2 delta, 49.8 delta, 50.7 delta, 55.5 delta, 59.7 delta, 75.6 delta, 75.6 delta, 101.8 delta, 119.1 delta, 121.8 delta, 126.3 delta, 126.7 delta, 127.3 delta, 129.1 delta, 131.7, delta143.1 delta, 144.7 delta, 144.9 delta, 147.5 delta, 152.1 delta, 154.8 delta, 157.7 delta.

1435-55-8 Hydroquinidine 16401293, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Patent; Massachusetts Institute of Technology; US5227543; (1993); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Category: 1435-55-8

Analyzing the synthesis route of 1435-55-8

Brief introduction of 1435-55-8